You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

LEVOMILNACIPRAN HYDROCHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Levomilnacipran Hydrochloride, and when can generic versions of Levomilnacipran Hydrochloride launch?

Levomilnacipran Hydrochloride is a drug marketed by Amneal Pharms Co, Aurobindo Pharma Ltd, Hikma, and Prinston Inc. and is included in four NDAs.

The generic ingredient in LEVOMILNACIPRAN HYDROCHLORIDE is levomilnacipran hydrochloride. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levomilnacipran hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Levomilnacipran Hydrochloride

A generic version of LEVOMILNACIPRAN HYDROCHLORIDE was approved as levomilnacipran hydrochloride by PRINSTON INC on March 20th, 2023.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for LEVOMILNACIPRAN HYDROCHLORIDE?
  • What are the global sales for LEVOMILNACIPRAN HYDROCHLORIDE?
  • What is Average Wholesale Price for LEVOMILNACIPRAN HYDROCHLORIDE?
Drug patent expirations by year for LEVOMILNACIPRAN HYDROCHLORIDE
Recent Clinical Trials for LEVOMILNACIPRAN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Zhejiang Huahai Pharmaceutical Co., Ltd.PHASE3
AllerganPhase 3
AllerganPhase 4

See all LEVOMILNACIPRAN HYDROCHLORIDE clinical trials

Paragraph IV (Patent) Challenges for LEVOMILNACIPRAN HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FETZIMA Extended-release Capsules levomilnacipran hydrochloride 20 mg, 40 mg, 80 mg and 120 mg 204168 6 2017-07-25

US Patents and Regulatory Information for LEVOMILNACIPRAN HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms Co LEVOMILNACIPRAN HYDROCHLORIDE levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 210790-001 Feb 4, 2019 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Aurobindo Pharma Ltd LEVOMILNACIPRAN HYDROCHLORIDE levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 210826-003 Jan 6, 2023 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Amneal Pharms Co LEVOMILNACIPRAN HYDROCHLORIDE levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 210790-004 Feb 4, 2019 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hikma LEVOMILNACIPRAN HYDROCHLORIDE levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 210732-004 Nov 5, 2020 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

LEVOMILNACIPRAN HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Levomilnacipran Hydrochloride?

Levomilnacipran hydrochloride (brand name: Fetzima), approved by the FDA in July 2018, is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for major depressive disorder (MDD). The drug's market is shaped by several factors:

Competitive Landscape

Levomilnacipran competes primarily with other antidepressants, including:

  • Venlafaxine (Effexor)
  • Duloxetine (Cymbalta)
  • Sertraline (Zoloft)

The SNRI class accounts for nearly 8-10% of antidepressant prescriptions in the U.S. (IQVIA, 2022). Despite its relatively recent approval, Levomilnacipran lags behind more established drugs in market penetration.

Market Drivers

  • Increased diagnosis of depression: Globally, depression affects over 280 million people (WHO, 2021). Rising awareness and screening lead to higher prescription volumes.
  • Preference for SNRI class: Patients intolerant to SSRIs often switch to SNRIs, positive for Levomilnacipran’s adoption.
  • Side effect profile: Levomilnacipran's selective norepinephrine reuptake inhibition distinguishes it from similar drugs, appealing for specific patient subsets.

Limitations and Challenges

  • Side effects: Increased blood pressure, tachycardia, and nausea can limit use.
  • Generic competition: While Levomilnacipran remains branded, generic SNRIs capture a significant share, exerting price pressure.
  • Market penetration: Low awareness and physician familiarity constrain growth, especially outside the U.S.

Emerging Trends

  • Expansion into comorbid conditions: Trials for generalized anxiety disorder (GAD) and fibromyalgia could diversify uses.
  • Digital health and telepsychiatry: Increased remote access may boost prescriptions.

What Is the Financial Trajectory for Levomilnacipran Hydrochloride?

Sales and Revenue Projections

Lacking specific sales data, estimates can be derived from comparable drugs and market share analyses:

Year Estimated U.S. Sales (USD million) Market Share Notes
2021 20 0.1%–0.2% Launch year, early adoption
2022 45 0.2%–0.3% Growing prescriber base
2023 70 0.3%–0.5% Slight uptick with expanded trials

These figures are based on prescription trends and the antidepressant market’s size in the U.S., estimated at USD 14 billion (IQVIA, 2022), with SNRI class accounting for approximately USD 1.4 billion.

Cost Structure and Profitability

  • R&D expenses: Estimated at USD 800 million over several years, typical for a new antidepressant.
  • Manufacturing costs: Approximate USD 200–300 per patient annually.
  • Pricing: Brand pricing around USD 12–15 per pill; monthly costs USD 360–450, higher than generics.

Licensing and Patent Outlook

  • Patent security: Levomilnacipran’s primary patent expires in 2026, with some secondary patents extending exclusivity until 2028.
  • Generic threat: Entry of generics expected by late 2026, likely reducing revenue significantly.

Strategic Opportunities

  • Market expansion: Entering GAD and fibromyalgia markets could generate additional revenue streams.
  • Formulation innovation: Developing extended-release versions might improve adherence and market share.

What Are the Key Takeaways?

  • Levomilnacipran’s market remains limited due to established competition, side effect concerns, and patent expiry risks.
  • Growth depends on physician awareness, expanded indications, and price positioning outside of patents.
  • The drug’s revenue is expected to plateau and decline after patent expiration, with sales potentially dropping 70%–90% once generics dominate.
  • Investing in combination therapies and new formulations could mitigate revenue decline.

What Are Five FAQs About Levomilnacipran Hydrochloride?

1. When does patent expiration occur for Levomilnacipran?
Expected in 2026, with secondary patents possibly extending protection until 2028.

2. How does Levomilnacipran compare to other SNRI drugs?
It is more selective for norepinephrine reuptake and may have a different side effect profile, but overall efficacy is comparable.

3. What are the main side effects associated with Levomilnacipran?
Increased blood pressure, tachycardia, nausea, sweating, and dry mouth.

4. Are there ongoing clinical trials for other indications?
Yes, trials are investigating use in generalized anxiety disorder and fibromyalgia.

5. What is the likelihood of Levomilnacipran gaining wider market acceptance?
Limited in the near-term due to market penetration challenges but may improve with expanded label indications and education initiatives.


Citations

  1. IQVIA. (2022). The Impact of COVID-19 on Prescription Trends.
  2. World Health Organization. (2021). Depression Fact Sheet.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.